Description
B7-33 Peptide Vial Australia
B7-33 has been discovered as one of the most potent anti-fibrotic peptides. Reducing fibrosis is a significant target of acute and chronic disease studies, including heart failure, lung inflammation, and others. In Australia animal experiments, a 50% reduction in fibrosis has boosted post-injury survival and is the first new treatment for heart failure in 20 years.
Also of interest is the use of B7-33 to reduce the reactivity of implanted medical devices to foreign substances. B7-ability 33’s capacity to minimise fibrous capsule formation in implanted medical devices by roughly 50% enables the improvement and development of implantable medical devices.
This particular peptide is not merely an anti-fibrotic agent. It can reduce blood pressure and protect the vascular, among its many other benefits. In addition, Australia animal studies suggest that B7-33 may be an effective treatment for preeclampsia, allowing more women to carry their babies to term in a manner that is safe for both mother and child.
Benefits of B7-33 Peptide Vial
- Research has shown B7-33 has anti-fibrotic properties
- Proven to reduce scarring
- Identified to reduce blood pressure
- Studies have suggested it has the capacity to make implanted medical devices more efficient and successful
- Could offer blood vessel protection
Amino Acid Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL
References:
https://pubmed.ncbi.nlm.nih.gov/32295457/
PLEASE NOTE: We do not supply Peptides or Sarms to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. All products listed on this website (https://aust.pharmagrade.store) and provided through Pharma Grade are intended ONLY FOR medical research purposes. Pharma Grade Australia does not encourage or promote the use of any of these products in a personal capacity (i.e. human consumption) nor are the products intended as a drug, stimulant or for use in any food products.